EZH2 dependent H3K27me3 is involved in epigenetic silencing of ID4 in prostate cancer

Oncotarget

Volumn 5, Issue 16, 2014, Pages 7172-7182

  Chinaranagari, Swathi ^a   Sharma, Pankaj ^a   Chaudhary, Jaideep ^a  

^a CLARK ATLANTA UNIVERSITY   (United States)

Author keywords

Epigenetics; EZH2; H3K27me3; ID4; Prostate cancer

Indexed keywords

DNA; DNA METHYLTRANSFERASE 1; HISTONE H3; HISTONE METHYLTRANSFERASE; LYSINE; LYSINE 27; POLYCOMB REPRESSIVE COMPLEX 2; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; EZH2 PROTEIN, HUMAN; HISTONE; ID4 PROTEIN, HUMAN; INHIBITOR OF DIFFERENTIATION PROTEIN; POLYCOMB GROUP PROTEIN;

AGED; ARTICLE; CANCER CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; DNA BINDING; DNA HELIX; DNA METHYLATION; EPIGENETICS; HISTONE MODIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METHYLATION; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; CASTRATION RESISTANT PROSTATE CANCER; GENE SILENCING; GENETIC EPIGENESIS; GENETIC TRANSFECTION; GENETICS; META ANALYSIS; METABOLISM; PROSTATE TUMOR; TUMOR CELL LINE;

CELL LINE, TUMOR; DNA METHYLATION; EPIGENESIS, GENETIC; GENE SILENCING; HISTONES; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEINS; MALE; POLYCOMB REPRESSIVE COMPLEX 2; POLYCOMB-GROUP PROTEINS; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TRANSFECTION;

EID: 84907066420     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2262     Document Type: Article

References (59)

1. Pagliuca A, Bartoli PC, Saccone S, Della Valle G and Lania L. Molecular cloning of ID4, a novel dominant negative helix-loop-helix human gene on chromosome 6p21.3-p22. Genomics. 1995; 27(1):200-203.
2. Sharma P, Knowell AE, Chinaranagari S, Komaragiri S, Nagappan P, Patel D, Havrda MC and Chaudhary J. Id4 deficiency attenuates prostate development and promotes PIN-like lesions by regulating androgen receptor activity and expression of NKX3.1 and PTEN. Mol Cancer. 2013; 12(1):67.
3. Sharma P, Chinaranagari S, Patel D, Carey J and Chaudhary J. Epigenetic inactivation of inhibitor of differentiation 4 (Id4) correlates with prostate cancer. Cancer Medicine. 2012;2(1)176-186.
4. Vinarskaja A, Goering W, Ingenwerth M and Schulz WA. ID4 is frequently downregulated and partially hypermethylated in prostate cancer. World journal of urology. 2012; 30(3):319-325.
5. Patel D, Knowell AE, Korang-Yeboah M, Sharma P, Joshi J, Glymph S, Chinaranagari S, Nagappan P, Palaniappan R, Bowen NJ and Chaudhary J. Inhibitor of differentiation 4 (ID4) inactivation promotes de novo steroidogenesis and castration resistant prostate cancer. Mol Endocrinol. 2014:me20141100.
6. Yu L, Liu C, Vandeusen J, Becknell B, Dai Z, Wu YZ, Raval A, Liu TH, Ding W, Mao C, Liu S, Smith LT, Lee S, Rassenti L, Marcucci G, Byrd J, et al. Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nat Genet. 2005; 37(3):265-274.
7. Liu F and Xu RR. [Study on the correlation between Chinese medical syndrome types and ID4 gene promoter methylation in human acute myeloid leukemia]. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine / Zhongguo Zhong xi yi jie he xue hui, Zhongguo Zhong yi yan jiu yuan zhu ban. 2012; 32(4):471-473.
8. Claus R, Wilop S, Hielscher T, Sonnet M, Dahl E, Galm O, Jost E and Plass C. A systematic comparison of quantitative high-resolution DNA methylation analysis and methylation-specific PCR. Epigenetics: official journal of the DNA Methylation Society. 2012; 7(7):772-780.
9. Borinstein SC, Conerly M, Dzieciatkowski S, Biswas S, Washington MK, Trobridge P, Henikoff S and Grady WM. Aberrant DNA methylation occurs in colon neoplasms arising in the azoxymethane colon cancer model. Mol Carcinog. 2010; 49(1):94-103.
10. Wang H, Wang XQ, Xu XP and Lin GW. ID4 methylation predicts high risk of leukemic transformation in patients with myelodysplastic syndrome. Leukemia research. 2010; 34(5):598-604.
11. Uhm KO, Lee ES, Lee YM, Park JS, Kim SJ, Kim BS, Kim HS and Park SH. Differential methylation pattern of ID4, SFRP1, and SHP1 between acute myeloid leukemia and chronic myeloid leukemia. Journal of Korean medical science. 2009; 24(3):493-497.
12. Chen SS, Claus R, Lucas DM, Yu L, Qian J, Ruppert AS, West DA, Williams KE, Johnson AJ, Sablitzky F, Plass C and Byrd JC. Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL. Blood. 2011; 117(3):862-871.
13. Hu HB and Hu Q. [ID4 methylation patterns in childhood T line and B line lymphocytic leukemia.]. Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics. 2010; 12(12):940-942.
14. Martini M, Cenci T, D'Alessandris GQ, Cesarini V, Cocomazzi A, Ricci-Vitiani L, De Maria R, Pallini R and Larocca LM. Epigenetic silencing of Id4 identifies a glioblastoma subgroup with a better prognosis as a consequence of an inhibition of angiogenesis. Cancer. 2013; 119(5):1004-1012.
15. Ruchusatsawat K, Wongpiyabovorn J, Protjaroen P, Chaipipat M, Shuangshoti S, Thorner PS and Mutirangura A. Parakeratosis in skin is associated with loss of inhibitor of differentiation 4 via promoter methylation. Hum Pathol. 2011; 42(12):1878-1887.
16. Chan AS, Tsui WY, Chen X, Chu KM, Chan TL, Li R, So S, Yuen ST and Leung SY. Downregulation of ID4 by promoter hypermethylation in gastric adenocarcinoma. Oncogene. 2003; 22(44):6946-6953.
17. Vincent A, Omura N, Hong SM, Jaffe A, Eshleman J and Goggins M. Genome-wide analysis of promoter methylation associated with gene expression profile in pancreatic adenocarcinoma. Clin Cancer Res. 2011; 17(13):4341-4354.
18. Carvalho B, Sillars-Hardebol AH, Postma C, Mongera S, Terhaar Sive Droste J, Obulkasim A, van de Wiel M, van Criekinge W, Ylstra B, Fijneman RJ and Meijer GA. Colorectal adenoma to carcinoma progression is accompanied by changes in gene expression associated with ageing, chromosomal instability, and fatty acid metabolism. Cell Oncol (Dordr). 2012; 35(1):53-63.
19. Gomez Del Pulgar T, Valdes-Mora F, Bandres E, Perez-Palacios R, Espina C, Cejas P, Garcia-Cabezas MA, Nistal M, Casado E, Gonzalez-Baron M, Garcia-Foncillas J and Lacal JC. Cdc42 is highly expressed in colorectal adenocarcinoma and downregulates ID4 through an epigenetic mechanism. Int J Oncol. 2008; 33(1):185-193.
20. Hagiwara K, Nagai H, Li Y, Ohashi H, Hotta T and Saito H. Frequent DNA methylation but not mutation of the ID4 gene in malignant lymphoma. Journal of clinical and experimental hematopathology: JCEH. 2007; 47(1):15-18.
21. Uhm KO, Lee ES, Lee YM, Kim HS, Park YN and Park SH. Aberrant promoter CpG islands methylation of tumor suppressor genes in cholangiocarcinoma. Oncology research. 2008; 17(4):151-157.
22. Smith E, De Young NJ, Pavey SJ, Hayward NK, Nancarrow DJ, Whiteman DC, Smithers BM, Ruszkiewicz AR, Clouston AD, Gotley DC, Devitt PG, Jamieson GG and Drew PA. Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma. Mol Cancer. 2008; 7:75.
23. Castro M, Grau L, Puerta P, Gimenez L, Venditti J, Quadrelli S and Sanchez-Carbayo M. Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer. Journal of translational medicine. 2010; 8:86.
24. Pagliuca A, Cannada-Bartoli P and Lania L. A role for Sp and helix-loop-helix transcription factors in the regulation of the human Id4 gene promoter activity. J Biol Chem. 1998; 273(13):7668-7674.
25. Margueron R and Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature. 2011; 469(7330):343-349.
26. Cao R and Zhang Y. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Current Opinion in Genetics & Development. 2004; 14(2):155-164.
27. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, Van Eynde A, Bernard D, Vanderwinden J-M, Bollen M, Esteller M, Di Croce L, de Launoit Y and Fuks F. The Polycomb group protein EZH2 directly controls DNA methylation. Nature. 2006; 439(7078):871-874.
28. Chang CJ and Hung MC. The role of EZH2 in tumour progression. Br J Cancer. 2012; 106(2):243-247.
29. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA and Chinnaiyan AM. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002; 419(6907):624-629.
30. Yang Y and Yu J. EZH2, an epigenetic driver of prostate cancer. Protein Cell. 2013; 4(5):331-341.
31. Goldman M, Craft B, Swatloski T, Ellrott K, Cline M, Diekhans M, Ma S, Wilks C, Stuart J, Haussler D and Zhu J. The UCSC Cancer Genomics Browser: update 2013. Nucleic Acids Res. 2013; 41(Database issue):D949-954.
32. Wang LF, Huang S, Huang C, Li CR and Li DJ. [Effect of 5-Aza-CdR on biological activity and inhibitor of DNA binding 4 gene expression in human erythroleukemia cell line K562]. Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / Chinese Association of Pathophysiology. 2011; 19(6):1388-1392.
33. Beke L, Nuytten M, Van Eynde A, Beullens M and Bollen M. The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2. Oncogene. 2007; 26(31):4590-4595.
34. Shin YJ and Kim JH. The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells. PLoS One. 2012; 7(1):e30393.
35. Taniguchi H, Jacinto FV, Villanueva A, Fernandez AF, Yamamoto H, Carmona FJ, Puertas S, Marquez VE, Shinomura Y, Imai K and Esteller M. Silencing of Kruppel-like factor 2 by the histone methyltransferase EZH2 in human cancer. Oncogene. 2012; 31(15):1988-1994.
36. Carey JP, Asirvatham AJ, Galm O, Ghogomu TA and Chaudhary J. Inhibitor of differentiation 4 (Id4) is a potential tumor suppressor in prostate cancer. BMC Cancer. 2009; 9:173.
37. Patel K, Dickson J, Din S, Macleod K, Jodrell D and Ramsahoye B. Targeting of 5-aza-2'-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme. Nucleic Acids Res. 2010; 38(13):4313-4324.
38. Kumar A, Kumar S, Vikram A, Hoffman TA, Naqvi A, Lewarchik CM, Kim YR and Irani K. Histone and DNA Methylation-Mediated Epigenetic Downregulation of Endothelial Kruppel-Like Factor 2 by Low-Density Lipoprotein Cholesterol. Arteriosclerosis, thrombosis, and vascular biology. 2013.
39. Sellers WR and Loda M. The EZH2 polycomb transcriptional repressor-a marker or mover of metastatic prostate cancer? Cancer Cell. 2002; 2(5):349-350.
40. Karanikolas BD, Figueiredo ML and Wu L. Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines. Prostate. 2010; 70(6):675-688.
41. Bryant RJ, Cross NA, Eaton CL, Hamdy FC and Cunliffe VT. EZH2 promotes proliferation and invasiveness of prostate cancer cells. The Prostate. 2007; 67(5):547-556.
42. Ren G, Baritaki S, Marathe H, Feng J, Park S, Beach S, Bazeley PS, Beshir AB, Fenteany G, Mehra R, Daignault S, Al-Mulla F, Keller E, Bonavida B, de la Serna I and Yeung KC. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. Cancer Res. 2012; 72(12):3091-3104.
43. Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA, Mehra R, Laxman B, Cao X, Kleer CG, Varambally S and Chinnaiyan AM. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene. 2008; 27(58):7274-7284.
44. Delcuve G, Khan D and Davie J. Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors. Clinical Epigenetics. 2012; 4(1):5.
45. Huang J, Vogel G, Yu Z, Almazan G and Richard S. Type II arginine methyltransferase PRMT5 regulates gene expression of inhibitors of differentiation/DNA binding Id2 and Id4 during glial cell differentiation. J Biol Chem. 2011; 286(52):44424-44432.
46. Gu Z, Li Y, Lee P, Liu T, Wan C and Wang Z. Protein Arginine Methyltransferase 5 Functions in Opposite Ways in the Cytoplasm and Nucleus of Prostate Cancer Cells. PLoS One. 2012; 7(8):e44033.
47. Komashko VM and Farnham PJ. 5-azacytidine treatment reorganizes genomic histone modification patterns. Epigenetics: official journal of the DNA Methylation Society. 2010; 5(3):229-240.
48. Herna´ndez-Muñoz I, Taghavi P, Kuijl C, Neefjes J and van Lohuizen M. Association of BMI1 with Polycomb Bodies Is Dynamic and Requires PRC2/EZH2 and the Maintenance DNA Methyltransferase DNMT1. Molecular and Cellular Biology. 2005; 25(24):11047-11058.
49. Smallwood A, Este`ve P-O, Pradhan S and Carey M. Functional cooperation between HP1 and DNMT1 mediates gene silencing. Genes & development. 2007; 21(10):1169-1178.
50. Hoffmann MJ, Engers R, Florl AR, Otte AP, Muller M and Schulz WA. Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer. Cancer Biol Ther. 2007; 6(9):1403-1412.
51. Carey JP, Knowell AE, Chinaranagari S and Chaudhary J. Id4 Promotes Senescence and Sensitivity to Doxorubicin-induced Apoptosis in DU145 Prostate Cancer Cells. Anticancer Res. 2013; 33(10):4271-4278.
52. Knowell A, Patel D, Morton D, Sharma P, Glymph S and Chaudhary J. Id4 dependent acetylation restores mutant-p53 transcriptional activity. Molecular Cancer. 2013; 12(1):161.
53. Lin MF, Meng TC, Rao PS, Chang C, Schonthal AH and Lin FF. Expression of human prostatic acid phosphatase correlates with androgen-stimulated cell proliferation in prostate cancer cell lines. J Biol Chem. 1998; 273(10):5939-5947.
54. Fanelli M, Amatori S, Barozzi I and Minucci S. Chromatin immunoprecipitation and high-throughput sequencing from paraffin-embedded pathology tissue. Nature protocols. 2011; 6(12):1905-1919.
55. Asirvatham AJ, Schmidt MA and Chaudhary J. Non-redundant inhibitor of differentiation (Id) gene expression and function in human prostate epithelial cells. Prostate. 2006; 66(9):921-935.
56. Sharma P, Patel D and Chaudhary J. Id1 and Id3 expression is associated with increasing grade of prostate cancer: Id3 preferentially regulates CDKN1B. Cancer Med. 2012; 1(2):187-197.
57. Noetzel E, Veeck J, Niederacher D, Galm O, Horn F, Hartmann A, Knuchel R and Dahl E. Promoter methylation-associated loss of ID4 expression is a marker of tumour recurrence in human breast cancer. BMC Cancer. 2008; 8:154.
58. Umetani N, Mori T, Koyanagi K, Shinozaki M, Kim J, Giuliano AE and Hoon DS. Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer. Oncogene. 2005; 24(29):4721-4727.
59. Umetani N, Takeuchi H, Fujimoto A, Shinozaki M, Bilchik AJ and Hoon DS. Epigenetic inactivation of ID4 in colorectal carcinomas correlates with poor differentiation and unfavorable prognosis. Clin Cancer Res. 2004; 10(22):7475-7483.